Literature DB >> 25973578

Primary Surgery vs Chemoradiation Treatment of Advanced-Stage Hypopharyngeal Squamous Cell Carcinoma.

Brianna N Harris1, Vincent L Biron1, Paul Donald1, D Gregory Farwell1, Quang C Luu1, Arnaud F Bewley1, Allen M Chen2, Megan E Daly3.   

Abstract

IMPORTANCE: There is no consensus whether primary surgery followed by either adjuvant radiotherapy (RT) or adjuvant chemoradiation (CRT) or definitive CRT should be the standard treatment approach to advanced-stage hypopharyngeal squamous cell carcinoma (HP SCC).
OBJECTIVES: To determine survival outcomes for patients with advanced-stage HP SCC treated at a single institution with either primary surgery plus RT or CRT or definitive CRT. EVIDENCE AND DATA ACQUISITION: We conducted a retrospective analysis of prospectively collected medical records in an institutional database for patients with HP SCC newly diagnosed between January 1999 and April 2013. Overall survival (OS) and recurrence-free survival (RFS) were calculated and compared between treatment groups using the Kaplan-Meier method, with multivariate Cox regression analysis used to control for demographic and clinicopathologic features.
RESULTS: We identified 166 consecutively treated patients, 90 of whom did not meet study criteria. Of the 76 included patients, 48 (63%) had undergone definitive CRT, and 28 (37%) had undergone primary surgery with adjuvant RT or CRT. The groups were well balanced by age, smoking history, and alcohol use. Five-year OS and RFS for patients treated surgically were 66.3% and 53.6%, respectively; for patients treated with definitive CRT, OS and RFS were 41.3% and 34.5%, respectively. Multivariate Cox regression analysis showed that surgical management was associated with clinically improved OS (hazard ratio [HR], 4.78; 95% CI, 0.91-25.03; P = .06) and RFS (HR, 2.97; 95% CI, 0.76-11.53; P = .12), although the difference was not statistically significant. CONCLUSIONS AND RELEVANCE: Patients with advanced-stage HP SCC treated surgically with adjuvant RT or CRT showed a trend toward clinically improved OS and RFS compared with patients treated with definitive CRT. However, the difference was not statistically significant, and further investigation with larger controlled trials using modern approaches should be undertaken to optimize the initial management of advanced-stage HP SCC.

Entities:  

Mesh:

Year:  2015        PMID: 25973578     DOI: 10.1001/jamaoto.2015.0659

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  12 in total

1.  Organ preservation vs primary surgery in the management of T3 laryngeal and hypopharyngeal cancers.

Authors:  Sudhir Vasudevan Nair; Manish Mair; Noopur Sawarkar; Swagnik Chakrabarti; Burhanuddin Qayyumi; Deepa Nair; Pankaj Chaturvedi; Tejpal Gupta; Jai Prakash Agrawal
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-29       Impact factor: 2.503

2.  A Survival Analysis of Hypopharyngeal Cancer Patients: A Hospital-Cancer registry Based Study.

Authors:  Manigreeva Krishnatreya; Amal Chandra Kataki; Jagannath Dev Sharma; Nizara Baishya; Tashnin Rahman; Mouchumee Bhattcharyya; Ashok Kumar Das; Manoj Kalita
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-12-27

3.  Microarray gene expression analysis of chemosensitivity for docetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma.

Authors:  Meng Lian; Haizhou Wang; Jugao Fang; Jie Zhai; Ru Wang; Xixi Shen; Yifan Yang; Zhihong Ma; Honggang Liu
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

4.  Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer.

Authors:  Sang-Yeon Kim; Young-Soo Rho; Eun-Chang Choi; Min-Sik Kim; Joo-Hyun Woo; Dong Hoon Lee; Eun Jae Chung; Min Woo Park; Da-Hee Kim; Young-Hoon Joo
Journal:  BMC Cancer       Date:  2017-12-29       Impact factor: 4.430

5.  Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population-based study.

Authors:  Yi-Jun Kim; Rena Lee
Journal:  Cancer Med       Date:  2018-11-26       Impact factor: 4.452

6.  Management of Advanced-stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center.

Authors:  Toms Vengaloor Thomas; Mary R Nittala; Eldrin Bhanat; Ashley A Albert; Srinivasan Vijayakumar
Journal:  Cureus       Date:  2020-01-16

7.  Development and validation of a nomogram to predict cancer-specific survival in patients with hypopharyngeal squamous cell carcinoma treated with primary surgery.

Authors:  Ke Wang; Xia Xu; Ruotao Xiao; Danyi Du; Luqi Wang; Hanqing Zhang; Zehong Lv; Xiangping Li; Gang Li
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

8.  Silencing Ras-Related C3 Botulinum Toxin Substrate 1 Inhibits Growth and Migration of Hypopharyngeal Squamous Cell Carcinoma via the P38 Mitogen-Activated Protein Kinase Signaling Pathway.

Authors:  Huijuan Cheng; Weiwei Wang; Guangke Wang; Anran Wang; Linfang Du; Weihua Lou
Journal:  Med Sci Monit       Date:  2018-02-07

9.  The presence of risk factors and corresponding treatment strategies post-surgical resection in stage IV hypopharyngeal squamous cell carcinoma patients: a retrospective cohort study.

Authors:  Yu Heng; Xiaoke Zhu; Liang Zhou; Ming Zhang; Hong Zhou; Lei Tao
Journal:  Ann Transl Med       Date:  2020-03

10.  A novel prognostic model predicting the long-term cancer-specific survival for patients with hypopharyngeal squamous cell carcinoma.

Authors:  Xin Tang; Tong Pang; Wei-Feng Yan; Wen-Lei Qian; You-Ling Gong; Zhi-Gang Yang
Journal:  BMC Cancer       Date:  2020-11-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.